ArticleJournal of neurology2026
Anxiety and depression as prodromes of Parkinson's disease: prospective findings from the Moli-sani study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- C-terminal Domain of the Heavy Chain of Tetanus Toxin Ameliorate Lipopolysaccharide Induced Hemiparkinsonism in Rats.Neurotoxicity research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Anxiety or depression are considered prodromes of Parkinson's disease (PD), though their temporal pattern is not fully defined. This study investigates the temporal relationship between drug-treated anxiety or depression and the clinical onset of PD motor symptoms.We used data from the Moli-sani study, which included 23,395 participants (52% women; mean age 55 ± 12 years, 15 year median follow-up). Participants free of PD at baseline were classified as either non-exposed (N = 20,033) or as having anxiety or depression (N = 1,760), based on both self-reporting and documented use of appropriate medications. Individuals with only one criterion (N = 1,602) were analysed separately. Incident PD cases were identified through regional health records and validated by neurologists and medical records. We used Cox models with inverse probability weighting based on propensity scores.A total of 306 PD cases were recorded (337,372 person-years). Individuals with both self-reported anxiety or depression and medication use had double PD hazard versus non-exposed (HR = 2.02, 95%CI: 1.45-2.80). This association was confirmed with validated PD cases (N = 144; HR = 1.96; 95%CI: 1.21-3.17), and was more evident in those treated for both conditions (N = 395; HR = 3.18, 95%CI: 1.90-5.31). No association emerged for those meeting only one criterion. Excluding subjects with a progressively shorter interval between the onset of anxiety or depression and study exit clearly attenuated the association, which nearly disappeared when the interval was > 10 years. The temporal pattern observed suggests that anxiety and depression requiring pharmacological treatment may represent time-dependent prodromal manifestations of clinical PD, emerging up to 10 years before motor symptoms.
Indexed as
Identifiers
41772237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.